Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1555-1560

  Komohara, Yoshihiro ^a   Harada, Mamoru ^a   Arima, Yoshimi ^a   Suekane, Shigetaka ^a   Noguchi, Masanori ^a   Yamada, Akira ^a,b   Itoh, Kyogo ^a,b   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Bladder cancer; EZH2; HLA A24; MRP3; Peptide vaccine; SART3

Indexed keywords

CANCER VACCINE; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; HLA A ANTIGEN; HLA A24 ANTIGEN; IMMUNOGLOBULIN G; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3; RNA BINDING PROTEIN; SART3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HLA-A ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA, MESSENGER; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS; URINARY BLADDER NEOPLASMS;

EID: 39049185212     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1555     Document Type: Article

References (38)

1. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19: 573-580, 1992.
2. Sohle A and Brandau S: Immune mechanisms in Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170: 964-969, 2003.
3. Perabo FGE and Muller SC: Current and new strategies in immunotherapy for superficial bladder cancer. Urology 64: 409-421, 2004. (Pubitemid 39200724)
4. Mine T, Sato Y, Noguchi M, et al: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10: 929-937, 2004.
5. Vieweg J and Dannull J: Technology insight:vaccine therapy for prostate cancer. Nat Clin Pract Urol 2: 44-51, 2005. (Pubitemid 40823154)
6. Srivastava PK: Therapeutic cancer vaccines. Curr Opin Immunol 18: 201-205, 2006.
7. Lewis JJ: Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci USA 101: 14653-14656, 2004.
8. Pardoll DM: Cancer vaccines. Immunol Today 14: 310-316, 1994.
9. Murayama K, Kobayashi T, Imaizumi T, et al: Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 23: 511-518, 2000.
10. Miyagi Y, Imai M, Sasatomi T, et al: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 7: 3950-3962, 2001.
11. Suzuki N, Maeda Y, Tanaka S, Hida N, Mine T, Yamamoto K, Oka M and Itoh K: Detection of peptide-specific cytotixic Tlymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer 98: 45-50, 2002. (Pubitemid 34113417)
12. Sasatomi T, Suefuji Y, Matsunaga K, et al: Expression of tumor rejection antigens in colorectal carcinomas. Cancer 94: 1636-1641, 2002. (Pubitemid 34241098)
13. Yamada A, Kawano K, Koga M, Matsumoto T and Itoh K: Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 61: 6459-6466, 2001.
14. + prostate cancer patients. Prostate 60: 273-281, 2004.
15. Kawagoe N, Shintaku I, Yutani S, Etoh H, Matuoka K, Noda S and Itoh K: Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 164: 2090-2095, 2000.
16. Yang D, Nakao M, Shichijo S, et al: Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056-4063, 1999.
17. Tanaka S, Tsuda N, Kawano K, et al: Expression of tumor-rejection antigens in gynecologic cancers. Jpn J Cancer Res 91: 1177-1184, 2000.
18. Gohara R, Imai N, Rikimaru T, et al: Phase I clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J Immunother 25: 439-444, 2002.
19. + non-small cell lung cancer patients. Eur J Cancer 40: 1776-1786, 2004.
20. + cancer patients. Int J Oncol 24: 967-975, 2004.
21. Hida N, Maeda Y, Katagiri K, Takasu H, Harada M and Itoh K: A simple culture protocol to detect peptide-specific T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51: 219-228, 2002. (Pubitemid 34493956)
22. Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K and Harada M: Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 11: 6933-6943, 2005.
23. Sato Y, Maeda Y, Shomura H, et al: A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 90: 1334-1342, 2004.
24. Shomura H, Shichijo S, Matsueda S, Kawakami T, Sato Y, Todo S and Itoh K: Identification of epidermal growth factor receptor-derived peptides immunogenetic for HLA-A2(+) cancer patients. Br J Cancer 90: 1563-1571, 2004. (Pubitemid 38648239)
25. Yamamoto K, Mine T, Katagiri K, et al: Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer. Oncol Rep 13: 874-883, 2005.
26. Yajima N, Yamanaka R, Mine T, et al: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11: 5900-5911, 2005.
27. Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, and Nexo F: The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer 94: 1703-1709, 2006. (Pubitemid 43924936)
28. La Rue H, Parent-Vaugeois C, Bergeron A, Champetier S and Fradet Y: Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer. Int J Cancer 71: 986-992, 1997. (Pubitemid 27252881)
29. Modjtahedi H, Moscatello DK, Box G, et al: Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumor therapy. Int J Cancer 105: 273-280, 2003.
30. Tada Y, Wada M, Migita T, et al: Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 98: 630-635, 2002. (Pubitemid 34208567)
31. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS and Gudas LJ: Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570-8576, 2005. (Pubitemid 43005902)
32. Arisan S, Buyultuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO and Ergenekon F: Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75: 252-257, 2005. (Pubitemid 41433876)
33. Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K and Kause H: Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16: 349-353, 2005.
34. Kool M, De Haas M, Scheffer GL, et al: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547, 1997.
35. Laible G, Wolf A, Dorn R, et al: Mammalian homologues of the Polycomb-group gene enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 16: 3219-3232, 1997.
36. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003.
37. + cancer patients. Eur J Immunol 33: 2964-2973, 2003.
38. Kawamoto N, Yamada A, Ohkouchi S, et al: IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients. Tissue Antigens 61: 352-361, 2003.